SelectQuote’s (SLQT) Cash Flow Pitch Comes With A Shrinking Top Line

SelectQuote (NASDAQ:SLQT) recently unveiled a cash flow-focused outlook, emphasizing revenue growth over profit. For fiscal 2026, the company reported revenue of $1.62 billion, a 6% increase year-over-year, and operating cash flow of $44 million, a notable rise. However, the same report revealed a $16.8 million net loss for the quarter, a reversal from the $12.9 million net income in the previous year.

Management expects operating cash flow to reach $60 million or more in fiscal 2027, but guidance shows a significant decline in revenue, projecting $1.35 billion to $1.45 billion, a 14% decrease from the previous year. The company's healthcare services segment, which includes SelectRx pharmacy, generated $845 million in revenue, up 14% despite inflation reduction act drug pricing changes.

The segment's annualized adjusted EBITDA run rate is nearly $50 million, almost double the $25 million produced in the full year. Management anticipates further margin expansion as more prescriptions go through their Olathe facility, which has seen a 30% efficiency improvement. Additionally, SelectQuote has identified $30 million in annualized savings from AI-enabled enrollment tools and workflow automation.

However, the company's fiscal 2027 guide projects a decline in Medicare Advantage approved policies, dropping 10% to 15%. Senior segment revenue dropped 4% in fiscal 2026, partly due to a major carrier partner reducing its marketing spending. The Inflation Reduction Act will continue to pressure Healthcare Services revenue through fiscal 2027.

SelectQuote carries $800 million in debt and preferred equity, resulting in $45 million in annual cash interest. Despite the challenges, hedge fund ownership has increased, and short interest remains low. The stock trades at a forward price-to-earnings ratio of 66.67, reflecting expectations of future earnings growth.